Skip to main content

Advertisement

SpringerLink
Log in

Case Presentations from the Addiction Academy

  • Proceedings
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

In this article, a case-based format is used to address complex clinical issues in addiction medicine. The cases were developed from the authors’ practice experience, and were presented at the American College of Medical Toxicology Addiction Academy in 2015. Section I: Drug and Alcohol Dependence and Pain explores cases of patients with co-occurring pain and substance use disorders. Section II: Legal and Policy Issues in Substance Use Disorders highlights difficult legal and policy questions in addiction medicine. Section III: Special Populations and Addictive Disorders delves into the complexity of addiction in special populations (pregnant, pediatric, and geriatric patients).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Neven DE, Sabel JC, Howell DN, Carlisle RJ. The development of the Washington state emergency department opioid prescribing guidelines. J Med Toxicol. 2012;8:353–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63:881–5.

    PubMed  Google Scholar 

  3. Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother. 2015;49:14–9.

    Article  PubMed  Google Scholar 

  4. Grosu I, Lavand’homme P. Use of dexmedetomidine for pain control. F1000 Med. Rep. [Internet]. 2010 [cited 2015 Nov 1];2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026617/

  5. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144:127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-5). Washington, DC: American Psychiatric Association; 2013.

  7. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6:432–42.

    Article  PubMed  Google Scholar 

  8. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain Off J Am Pain Soc. 2008;9:360–72.

    Article  Google Scholar 

  9. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130:144–56.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253–9.

    Article  PubMed  Google Scholar 

  11. e-CFR: Title 21: Food and Drugs PART 1306—PRESCRIPTIONS [Internet]. Electron. Code Fed. Regul. Available from: http://www.ecfr.gov/cgi-bin/text-idx?SID=e9e3a02e7173339f0f9631cd9872ac60&pitd=20150101&node=se21.9.1306_107&rgn=div8

  12. TIP 40: clinical guidelines for the use of buprenorphine in the treatment of opioid Addiction|SAMHSA [Internet]. 2004 [cited 2015 Aug 31]. Available from: http://store.samhsa.gov/product/TIP-40-Clinical-Guidelines-for-the-Use-of-Buprenorphine-in-the-Treatment-of-Opioid-Addiction/SMA07-3939

  13. e-CFR: title 42: public health [internet]. Electron. Code Fed. Regul. Sect. Part 2—confidentiality of alcohol and drug abuse patient records. Available from: http://www.ecfr.gov/cgi-bin/text-idx?rgn=div5;node=42%3A1.0.1.1.2

  14. Model policy guidelines for opioid addiction treatment in the medical office [Internet]. Substance abuse and mental health services administration; [cited 2015 Aug 31]. Available from: http://buprenorphine.samhsa.gov/model.html

  15. Treatment C for SA, others. Medication-assisted treatment for opioid addiction during pregnancy. 2005 [cited 2015 May 17]; Available from: http://www.ncbi.nlm.nih.gov/books/NBK64148

  16. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25:139–51.

    Article  CAS  PubMed  Google Scholar 

  17. Jones HE, Martin PR, Heil SH, Stine SM, Kaltenbach K, Selby P, et al. Treatment of opioid dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35:245–59.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Debelak K, Morrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict Am Acad Psychiatr Alcohol Addict. 2013;22:252–4.

    Google Scholar 

  19. Meites E. Opiate exposure in breastfeeding newborns. J Hum Lact Off J Int Lact Consult Assoc. 2007;23:13.

    Google Scholar 

  20. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hudak ML, Tan RC. Committee on drugs, fetus, and newborns, American academy of pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129:e540–60.

    Article  PubMed  Google Scholar 

  22. Center for Substance Abuse Treatment. Treatment of adolescents with substance use disorders. Subst Abuse Ment Health Serv Aministration Treat Improv Protoc TIP 32. 1999.

  23. Knight JR, Sherritt L, Shrier LA, Harris S, Chang G. VAlidity of the crafft substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156:607–14.

    Article  PubMed  Google Scholar 

  24. National Institute on Alcohol Abuse and Alcoholism. Alcohol screening and brief intervention for youth: a practitioner’s guide. US Dept Health Hum Serv 2011.

  25. Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al. Predictors of abstinence: national institute of drug abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry. 2011;50:1120–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62:1157–64.

    Article  CAS  PubMed  Google Scholar 

  27. Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Grucza RA, Bierut LJ. Youth tobacco use type and associations with substance use disorders. Addict Abingdon Engl. 2014;109:1371–80.

    Article  Google Scholar 

  28. Principles of Adolescent Substance Use Disorder Treatment: a research-based guide. National institute on drug abuse, Rockville, Maryland, National Institutes of Health; 2014.

  29. Midlöv DP, Eriksson DT, Kragh DA. Inappropriate Drugs in the Elderly. Drug-Relat. Probl. Elder. [Internet]. Springer Netherlands; 2009 [cited 2015 Jun 1]. p. 37–47. Available from: http://link.springer.com/chapter/10.1007/978-90-481-2446-6_4

  30. Ewing JA. Detecting alcoholism: the cage questionnaire. JAMA. 1984;252:1905–7.

    Article  CAS  PubMed  Google Scholar 

  31. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971;127:1653–8.

    Article  CAS  PubMed  Google Scholar 

  32. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

    Article  CAS  PubMed  Google Scholar 

  33. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Addiction Medicine, Hennepin County Medical Center, 701 Park Avenue, Mail Code G5, Minneapolis, MN, 55415, USA

    JoAn R. Laes

  2. University of Rochester Medical Center & Strong Memorial Hospital, Rochester, NY, USA

    Timothy Wiegand

Authors
  1. JoAn R. Laes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Wiegand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to JoAn R. Laes.

Appendix

Appendix

JoAn R. Laes, MD

Petro Levounis, MD, MA, FASAM

Daniel L. Sudakin, MD, MPH, FACMT

Edwin A. Salsitz, MD, FASAM

Timothy Wiegand, MD, FACMT (Moderator)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laes, J.R., Wiegand, T. Case Presentations from the Addiction Academy. J. Med. Toxicol. 12, 82–94 (2016). https://doi.org/10.1007/s13181-015-0520-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-015-0520-x

Keywords

Search

Navigation